Table 3.
Systematic biopsies reduced versus csPCa detected and/or missed by cognitive MRTB in the development and validation cohorts using different biopsy strategies
| Threshold | Models | The development cohort (n = 201) | The validation cohort (n = 73) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of SB performed | No. of SB reduced | No. csPCa detected by MRTB | No. csPCa missed by MRTB | No. of SB performed | No. of SB reduced | No. csPCa detected by MRTB | No. csPCa missed by MRTB | ||
| 50% | Clinical | 105 (52.2%) | 96 (47.8%) | 99 (99%) | 1 (1%) | 53 (72.6%) | 20 (27.4%) | 32 (94.1%) | 2 (5.9%) |
| MRI | 98 (48.8%) | 103 (51.2%) | 98 (98%) | 2 (2%) | 39 (53.4%) | 34 (46.6%) | 33 (97.1%) | 1 (2.9%) | |
| Advanced | 106 (52.7%) | 95 (47.3%) | 98 (98%) | 2 (2%) | 41 (56.2%) | 32 | 33 (97.1%) | 1 (2.9%) | |
| 60% | Clinical | 105 (52.2%) | 96 (47.8%) | 99 (99%) | 1 (1%) | 53 (72.6%) | 20 (27.4%) | 32 (94.1%) | 2 (5.9%) |
| MRI | 108 (53.7%) | 93 (46.3%) | 98 (98%) | 2 (2%) | 39 (53.4%) | 34 (46.6%) | 33 (97.1%) | 1 (2.9%) | |
| Advanced | 113 (56.2%) | 88 (43.8%) | 99 (99%) | 1 (1%) | 41 (56.2%) | 32 (43.8%) | 33 (97.1%) | 1 (2.9%) | |
| 70% | Clinical | 156 (77.6%) | 45 (22.4%) | 99 (99%) | 1 (1%) | 53 (72.6%) | 20 (27.4%) | 32 (94.1%) | 2 (5.9%) |
| MRI | 129 (64.2%) | 72 (35.8%) | 98 (98%) | 2 (2%) | 39 (53.4%) | 34 (46.6%) | 33 (97.1%) | 1 (2.9%) | |
| Advanced | 130 (64.7%) | 71 (35.3%) | 99 (99%) | 1 (1%) | 48 (65.8%) | 25 (34.2%) | 33 (97.1%) | 1 (2.9%) | |
| 80% | Clinical | 187 (93.0%) | 14 (7.0%) | 100 (100%) | 0 (0%) | 53 (72.6%) | 20 (27.4%) | 32 (94.1%) | 2 (5.9%) |
| MRI | 175 (87.1%) | 26 (12.9%) | 100 (100%) | 0 (0%) | 48 (65.8%) | 25 (34.2%) | 33 (97.1%) | 1 (2.9%) | |
| Advanced | 137 (68.2%) | 64 (31.8%) | 99 (99%) | 1 (1%) | 48 (65.8%) | 25 (34.2%) | 33 (97.1%) | 1 (2.9%) | |
| 90% | Clinical | 201 (100%) | 0 (0%) | 100 (100%) | 0 (0%) | 53 (72.6%) | 20 (27.4%) | 32 (94.1%) | 2 (5.9%) |
| MRI | 177 (88.1%) | 24 (11.9%) | 100 (100%) | 0 (0%) | 52 (71.2%) | 21 (28.8%) | 33 (97.1%) | 1 (2.9%) | |
| Advanced | 164 (81.6%) | 37 (18.4%) | 100 (100%) | 0 (0%) | 49 (67.1%) | 24 (32.9%) | 33 (97.1%) | 1 (2.9%) | |
| – | PI-RADS 5 | 143 (71.1%) | 58 (28.9%) | 98 (98%) | 2 (2%) | 55 (75.3%) | 18 (24.7%) | 33 (97.1%) | 1 (2.9%) |
Note: Data in percentages are percentages of all performed additional systematic biopsies or all clinically significant prostate cancers (csPCas) detected by cognitive MRI-target biopsy
PI-RADS Prostate Imaging Reporting and Data System, MRTB MRI-targeted biopsy, SB systematic biopsy